key: cord-0856944-3wff16h0
authors: Zein, Joe G.; Mitri, Jad; Bell, Jordan M.; Lopez, Diana; Strauss, Ronald; Attaway, Amy H.
title: The relationship of asthma severity to COVID-19 outcomes
date: 2021-10-27
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.10.041
sha: c40e39a0b260c2c993da74c31d1ab882761bc786
doc_id: 856944
cord_uid: 3wff16h0

nan

The ongoing Coronavirus Disease 2019 (COVID-19) pandemic continues to represent a major threat to public health with poor outcomes associated with obesity, age, male sex, African American race, tobacco use, and comorbidities.(1) The impact of asthma on COVID-19 severity is controversial and confounded by asthma severity, T2 inflammation, and inhaled corticosteroids (iCS). (2) (3) (4) (5) A recent analysis of electronic health records (EHR) from 61,338 patients with COVID-19 (5) found that adults with active but not inactive asthma were at higher risk for COVID-19-related hospitalization and admission to the intensive care unit (ICU)4. Of note, active asthma was not associated with increased COVID-19-related mortality. (5) To better understand the effect of asthma severity on COVID-19-related outcomes, we analyzed data from Cleveland Clinic's COVID-19 Research Registry (CCCRR) between April 1 st , 2020 and March 31 st , 2021.(6) Patients younger than 18 years or extreme body mass were excluded (see Figure E1 in this article's Online Repository at www.jaci-inpractice.org). We considered patients to have active asthma if they were prescribed an asthma medication or had asthma-related ICD-CM 10 billing codes listed in the EHR within one year of their positive COVID-19 result (Table I) (5) . We defined severe asthma based on the Global Initiative for Asthma (GINA) steps 4 and 5 (Table II) for those treated with high-dose iCS equivalent to or exceeding 800 µg/day of budesonide. We then used the most recent ICD-CM 10 codes to stratify asthma severity into mild (J45.20; J45.30), moderate (J45.40), or severe (J45.50). (7) Multivariable logistic regression was performed comparing severe COVID-19 (defined by COVID-19-related hospitalization, ICU admission, or death) to asthma J o u r n a l P r e -p r o o f severity and GINA treatment steps. Regression models were adjusted for covariates a priori known to be associated with severe COVID-19(1) (i.e. demographics, BMI, smoking status, pack-years, comorbidities, and medications) ( , but not death. Otherwise, we did not find any other significant association between asthma and critical illness or mortality (Table II) . These findings were replicated in sensitivity analyses after adjustment for pre-existing eosinophilia (> 300 cells/µL) in a subset of 43,104 individuals (see Table E1 in this article's Online Repository at www.jaci-inpractice.org).

Among patients with active asthma, 1562 (25.4%) had a single exacerbation (defined by oCS prescription less than 28 days), and 290 (4.7%) had frequent (≥2) exacerbations the 12 months prior to COVID-19. Additional adjustments for asthma therapies did not find an association between asthma exacerbation and severe COVID-19 (Table II) . These data suggest that COVID-19-related hospitalization is associated with severe asthma but not asthma control as reflected by the number of exacerbations.

In our study, increased risk of COVID-19-related hospitalization among asthmatics did not translate into a higher risk for ICU admission or death. To date, studies associating asthma and COVID-19 outcomes have revealed conflicting results likely due to differences in research methodology, data type, country of origin, the presence or absence of T2 inflammation, iCS use, and sample size. Our study has several limitations. Similar to other observational studies, our study could be subject to bias introduced by measured and unmeasured confounding factors.

With this real-world data extracted from EHR, it was not possible to use standardized international consensus-based definitions to identify severe asthma. Instead, we used asthma medication usage and billing codes to estimate asthma severity. (7) Our study is also limited by the lack of pharmacy claim data necessary to estimate medication (re)fill adherence measures, and did not account for patients admitted or died outside the Cleveland Clinic. All these limitations impose an inherent risk for bias by relying on electronic records. However, our strengths include rigorous methodologies as CCCRR data were extracted prospectively using uniform clinical templates to standardize patient care and facilitate data extraction. Data were then verified independently by trained medical personnel. (6) We aimed at improving our methods by using current asthma therapy as an additional criterion to define "active asthma".(5) We used two different methods to estimate asthma severity and found similar results. Finally, we adjusted our analyses for risk factors previously associated with severe COVID-19 and provided stratified analyses to test the association of asthma severity, asthma medication categories, and asthma exacerbations with COVID-19 outcomes. Although our data suggest that the risk of COVID-19-related hospitalizations is higher in severe asthma, randomized controlled trials and prospective observational studies of large asthma cohorts are needed to better understand the association between asthma and COVID-19 outcomes and to study the role of iCS in COVID-19, which is a frequent confounder for asthma severity. .001 Data are presented as n (%) for categorical variables and median [IQR] for continuous variables. iCS stands for inhaled corticosteroids; LABA for long-acting beta agonist; NSAIDs for nonsteroidal anti-inflammatory drugs; ACE for angiotensin converting enzyme, ARB for angiotensin receptor blocker; ICU for intensive care unit; OR for odds ratio and CI for confidence interval. *Data on high dose inhaled corticosteroids without long-acting beta agonist are not reported due to very small number (n21 patients). Data with <10 patients are listed as NA †Asthma medications used to differentiate between active and inactive asthma are: short acting beta agonists (SABA), leukotriene receptor antagonist (LTRA), inhaled corticosteroids (iCS), long-acting beta agonists (LABA) and long-acting muscarinic antagonist (LAMA) §Triple Therapy = iCS + LAMA +LABA ¶Group means were compared using the Kruskal-Wallis test.

Factors associated with COVID-19-related death using OpenSAFELY

Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK

Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform

Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying?

Asthma Disease Status, COPD, and COVID-19 Severity in a Large Multiethnic Population. The journal of allergy and clinical immunology In practice

Intranasal Corticosteroids Are Associated with Better Outcomes in Coronavirus Disease 2019. The journal of allergy and clinical immunology In practice

Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry

Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial

Acute lung injury induces cardiovascular dysfunction: effects of IL-6 and budesonide/formoterol. American journal of respiratory cell and molecular biology

.17] § iCS stands for inhaled corticosteroid; LABA for long-acting beta agonist; LAMA for long-acting muscarinic antagonist; IgE for Immunoglobulin E; ICU for intensive care unit; OR for odds ratio; CI for confidence interval. IL5 for interleukin 5; IL5Rα for interleukin 5 receptor alpha, and IL4Rα for interleukin 4 receptor alpha. *Hospital mortality also includes patients discharged to hospice. †Triple Therapy: iCS +LABA +LAMA; Anti IgE Biologic = Omalizumab; Anti IL5(Rα), IL4Rα Biologic Therapies = Mepolizumab, Reslizumab, Benralizumab, and Dupilumab §p=0.08 ‡ includes additional adjustment for therapy (short-acting beta agonist, long-acting beta agonist, inhaled corticosteroids and long-acting muscarinic antagonist)Analyses adjusted for age, sex, race, ethnicity, body mass index, smoking history, packs years smoking, medications (NSAIDs, ACE inhibitor, angiotensin receptor blocker, intranasal corticosteroids), comorbidities (allergic rhinitis, diabetes, hypertension, coronary artery disease, heart failure, cancer (historical of or current), and immunosuppressive diseases), and the month of testing. We excluded 21 patients on high dose inhaled corticosteroids alone without LABA. Analyses were performed on imputed data. Data with missing dependent variables were excluded. All variables had less than 15% of missing data. Multiple imputations (five imputations) for missing variables were carried out using the MICE package in R, and separate results were pooled using Rubin's rules to obtain the final results.